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Salivary gland dysfunction1. Introduction
Sjögren's syndrome (SS) is an autoimmune disease characterized by
dysfunction and inﬂammation of the exocrine glands, such as the sali-
vary and lacrimal glands, as well as features of systemic autoimmunity.
Neither an initial trigger nor the mechanism(s) underlying this
exocrinopathy has been elucidated. Nonetheless, it was proposed that
in genetically predisposed individuals, various environmental factors
such as viral infections could cause aberrant epithelial cell activation
that results in a protracted inﬂammatory response both locally in the af-
fected glands and systemically (Nikolov and Illei, 2009). The histological
hallmark of SS is periductal inﬂammatory inﬁltration, which can vary
frommild to diffuse (Nikolov and Illei, 2009). SS can be seen alone (pri-
mary SS, pSS) or in association with other autoimmune rheumatic dis-
eases (secondary SS) (Vitali et al., 2002). In the present study, we
have focused on pSS in an effort to understand the etiology of salivary
gland (SG) hypofunction in this autoimmune disease.
Several hypotheses have been suggested for salivary epithelial cell
dysfunction in pSS, including both immune-independent and im-
mune-dependent mechanisms. Our previous ﬁndings have shown that
peripheral blood mononuclear cells (PBMCs), lymphocytic inﬁltrateslivary Gland Dysfunction Unit,
, MD, USA.
ss article under the CC BY license (htin submandibular glands and SG epithelial cells from patients with
pSS display a reduction in two key proteins associatedwith Ca2+ signal-
ing, stromal interactingmolecules 1 and 2 (STIM1 and STIM2) (Cheng et
al., 2012). STIM1 and STIM2 function as sensors of changes in the Ca2+
concentrations within the endoplasmic reticulum (ER) (Zhang et al.,
2005; Liou et al., 2005). It has been established that STIM1 detects a sub-
stantial depletion of ER-Ca2+, and responds by aggregating and
translocating to the cell peripherywhere it associateswith and activates
plasmamembrane calcium channels (e.g. ORAI1 and TRPC1) that medi-
ate Ca2+ entry. This type of Ca2+ entry mechanism is referred to as
store-operated Ca2+ entry (SOCE), which is critically required for the
function of various cell types including lymphocytes and SG cells. In
the latter, SOCE provides the critical Ca2+ ﬂuxes required for the regu-
lation and maintenance of prolonged ﬂuid secretion. SOCE also drives
Ca2+-dependent gene expression by triggering activation of transcrip-
tion factors such as NFAT (Cheng et al., 2011). Further, expression of
aquaporin 5 (AQP5), the apical plasma membrane water channel in
SGs (Catalan et al., 2009; Ishikawa et al., 2006), has also been reported
to be disrupted in SS tissues (Wang et al., 2009). AQP water channels
are abundant in a variety of cells for the transportation of ﬂuid
(Catalan et al., 2009)and AQP5 is predicted to have a signiﬁcant role in
ﬂuid secretion in acinar cells based on its abundance in the apical region
of those cells (Catalan et al., 2009). Numerous studies have also
highlighted a key role for B lymphocytes in autoimmune disease, in-
cluding pSS. SG inﬁltrates tend to contain increasing proportions of Btp://creativecommons.org/licenses/by/4.0/).
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is often observed in the most severe presentations of pSS (Voulgarelis
and Tzioufas, 2010). Furthermore, changes in the distribution of B-cell
subsets have been reported among circulating lymphocytes in pSS pa-
tients (Pers et al., 2008).
We have previously reported that microRNA (miRNA) expression
proﬁles in the minor SGs from healthy controls are signiﬁcantly differ-
ent from those in pSS patients (Alevizos et al., 2011). Also, pSS patients
display distinct sets of microRNAs that are associated with SG dysfunc-
tion with or without inﬂammation (Alevizos et al., 2011). One of the
previously identiﬁed microRNAs, ebv-miR-BART13, is encoded by the
Epstein-Barr virus (EBV) is highly expressed in the SGs of pSS patients
when compared to healthy individuals. In this stud,y we examine the
mechanistic link between ebv-miR-BART13-3p and SG dysfunction as-
sociated with pSS. As noted above, viral infection has been proposed
to serve as a trigger in the initiation of pSS. Several studies have also
linked EBV infection with systemic autoimmune diseases (Toussirot
and Roudier, 2008). EBV is a double-stranded DNA human-γ-herpesvi-
rus that replicates in nasopharyngeal cells and infects naïve B cells usu-
ally in childhood or during early adulthood, with more than 90% of
adults being infected with the virus (Nikolov and Illei, 2009). Entry of
EBV into cells is determined by the presence of its receptor, CD21, on
the cell surface (Nemerow et al., 1985) and even after the primary infec-
tion, the virus can persist in a latent form within memory B cells
(Woellmer and Hammerschmidt, 2013). Some studies have reported
an increased presence of EBV DNA in SGs of SS patients, but a direct
role of EBV in SG dysfunction has not been shown (Fox et al., 1986;
Mariette et al., 1991; Saito et al., 1989). The epithelial cell surface recep-
tors for EBV infection have not yet been identiﬁed. It has been shown
that normal nasopharyngeal epithelial cells are not permissive for latent
EBV infection, and EBV infection in normal nasopharyngeal epithelial
cells usually results in growth arrest. CD21 has been shown to be a crit-
ical component in the infection of epithelial cells as its overexpression
allows for a high infection efﬁciency (Li et al., 1992; Hutt-Fletcher,
2007). Other mechanisms of infection of epithelial cells by EBV have
been proposed but none has been validated or is accepted to the virolo-
gy community. It has been demonstrated thatmiRNAs secreted by EBV-
infected cells can be transferred to and act in uninfected recipient cells
(Pegtel et al., 2010). Based on these ﬁndings, we hypothesized that
ebv-miR-BART13-3p can be effectively transferred from EBV-infected
B lymphocytes to SG epithelial cells and may directly contribute to the
salivary dysfunction in pSS.
We report herein that ebv-miR-BART13-3p targets STIM1 and AQP5,
both of which are critical for SG function. Importantly, we show that
functional ebv-miR-BART13-3p can be transferred via exosomes from
B cells to salivary epithelial cells where it decreases STIM1 expression,
resulting in attenuation of SOCE and SOCE-regulated Ca2+-dependent
gene expression. Since loss of functional STIM1 protein, together with
AQP5 defects, can signiﬁcantly impact SG function, ourﬁndings uncover
a possible mechanistic link between EBV infection and SG
exocrinopathy in pSS.
2. Materials and Methods
2.1. Human Samples
All human samples and their derivatives were obtained from sub-
jects enrolled in IRB approved clinical protocols at the National Insti-
tutes of Health, Bethesda, USA. All subjects had signed the informed
consent prior to any procedures.
2.2. Cell Cultures and Transfection
HSG cells were cultured in Minimal Essential Medium Eagle (MEM)
supplemented with 10% fetal bovine serum and antibiotics while
human-derived primary epithelial cells (pSG) cells were cultured inKeratinocyte grown medium (Jang et al., 2014). For transfections,
2 × 105 cells were transfected for 48 h with 50 nM of ebv-miR-
BART13-3p mimic (QIAGEN, CA, USA) using the HiPerfect Trasfection
reagent (QIAGEN, CA, USA) according to the manufacturer's instruc-
tions. The EBV-positive B cell line X50-7was cultured in RPMI 1640me-
dium with 25 mM Hepes, 2 mM glutamine (Gibco Life Technologies,
Carlsbad, CA), 10% fetal calf serum(FCS) (Integro, Zaandam, TheNether-
lands), 100 IU/ml penicillin, and 50 μg/ml streptomycin (P/S). All other
reagents usedwere of molecular biology grade obtained from Sigma Al-
drich chemicals (Sigma Aldrich, St. Lo, MO) unless mentioned
otherwise.2.3. Co-culture of pSG and B-cells
X50-7 cells was plated in the Transwell® insert (transparent, 23mm
diameter, 0.4 μmpore size, Falcon). The inserts were placed in the com-
panion wells where pSG cells had been already cultured for 2 days. The
medium used for the coculture was the RPMI 1640 medium supple-
mented as stated above. As controls, the pSG cells were cultured alone
with the same medium used for X50-7 co-culture. All cultures were
fed for 7 days before cellswere harvested for further analyses. Exosomes
from co-culture experiments were isolated as described previously
(Gallo and Alevizos, 2013).2.4. Construction of Luciferase Plasmids
To validate the target site of ebv-miR-BART13-3p on the
human STIM1 transcript, the coding region and 3′-UTR fragments
of STIM1 were obtained through PCR. For coding region ampliﬁca-
tion, forward primer: 5′-ATGGATGctcgagGTCCGTCTTGCCCTGTG-3′
(small case, XhoI); reverse primer: 5′-
CTACTTCTTAAgcggccgcTTAAAGATGTCGACGGGAAACTTCTTCC-3′
(small case, Not1). For 3′-UTR fragment ampliﬁcation: forward
primer: 5′-GCAGGctcgagTGG CAGTAAAGGGACAGCT-3′; reverse
primer: 5′-TCTgcggccgcGCACCCTCCTAAGACCAG-3′ and STIM1
cDNAwas used as a template (Origene). The reaction was performed
with Advantage 2 polymerase (Clontech) at 94 °C, 2 min; 35 cycles of
94 °C, 30 s, 62 °C, 30 s, and 72 °C 3min; 72 °C, 10 min; 4 °C for 10min.
The PCR fragments were gel-puriﬁed, cleaned, digested with XhoI
and NotI, and cloned into XhoI/NotI digested psiCHECK-2 luciferase
vector (Promega, WI, USA) for pCK2-STIM1-3’UTR and pCK2-
STIM1-CDS, respectively. The inserts were conﬁrmed with DNA se-
quencing. Luciferase AQP5-3’UTR construct was purchased from
GeneCopoeia (Rockville, MD, USA).2.5. Luciferase Reporter Assays
HSG cells were co-transfected with the pCK2-STIM1-3’UTR lucifer-
ase construct, or the pCK2-STIM1-CDS luciferase construct together
with ebv-miR-BART13. For the NFAT/RE Luciferase experiment, we co-
transfected HSG cells with pGL4.30 (luc2P/NFAT-RE/Hygro) (Promega
WI, USA) and the ebv-miR-BART13-3p mimic microRNA (QIAGEN, CA,
USA). Luciferase plasmids and the ebv-miR-BART13-3p were
transfected using the Attractene Trasfection Reagent (QIAGEN, CA,
USA) according to the manufacturer's instructions. The expression of
Renilla luciferase (included in psiCHECK2 plasmid, Promega, WI, USA)
was used to monitor transfection efﬁciency. Forty-eight hours post-
transfection, luciferase activity was measured with Dual-Luciferase®
Reporter Assay System according to the manufacturer's instructions
(Promega,WI, USA) using FluostarOmega (BMGLabtech). For each con-
dition, the experimentwas conducted in quadruplicates and the lucifer-
ase activity in each sample was measured in duplicate assays. Results
are represented as the ratio of Fireﬂy to Renilla luciferase activity.
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STIM1 was detected by immunoﬂuorescence in HSG cells grown on
glass-bottomed culture dishes (MatTek, Ashland, MA) and transfected
with ebv-miR-BART13-3p. After 48 h, cells were washed with ice-cold
phosphate-buffered saline (PBS), and ﬁxed with 4% paraformaldehyde,
were blocked with 0.5% BSA in PBS with 10% donkey serum. After
blocking for 30 min at room temperature, a primary antibody against
STIM1 (Cell Signaling Technology Cat# 5668S RRID:AB_10828699)
was applied and incubated at 4 °C overnight. Samples were washed ex-
tensively and incubated with secondary antibodies Alexa Fluor 768-
conjugated (Invitrogen, CA, USA) for 1 h at room temperature, washed,
and mounted with VectaShield mounting medium containing DAPI.
Quantitation of the immunoﬂuorescent signal was performed by mea-
suring the area-normalized intensity across each image using the freely
available ImageJ software (ImageJ, RRID:SCR_003070) (Schneider et al.,
2012). CD21 and CD20 surface receptors were detected by immunoﬂu-
orescence on 5 μm sections of FFPE humanminor SG biopsies. The sam-
ples were boiled in citrate buffer pH 6.0 during 15 min to expose the
antigens to the antibodies. Mouse anti-CD20 (Abcam Cat# ab9475,
RRID:AB_307267) was detected with Alexa Fluor goat anti-mouse
(Thermo Fisher Scientiﬁc Cat# A-21121, RRID:AB_2535764), rabbit
anti-DC21 (Abcam Cat# ab9492, RRID:AB_307279) was detected with
Alexa Fluor goat anti-rabbit (Thermo Fisher Scientiﬁc Cat# A11009,
RRID:AB_10374433), and species- and isotype-matched non-speciﬁc
immunoglobulins were used (Jackson ImmunoResearch) as negative
controls. Sections were incubated with primary antibody for overnight
at 4 °C and secondary antibody for 1 h at RT. Sections were mounted
using a prolong gold anti fadewith DAPI (Invitrogen). In all cases the re-
sults were visualized using anOlympus IX81motorized invertedmicro-
scope (Olympus, Centre Valley, PA).
2.7. In Situ Hybridization
In situ hybridization of ebv-miR-BART13-3p was performed in six
biopsies: 2 from healthy volunteers and 4 from SS patients by the fol-
lowing procedure (not all slides shown). The healthy volunteers were
both Caucasian, females, with no inﬂammatory foci in the salivary
glands, negative for the SS speciﬁc autoantibodies, 44 and 47 years
old. The SS subjects all fulﬁlled the American-European criteria for SS
classiﬁcation for primary SS, were all females, Caucasia, anti-SSA auto-
antibody positive, had a biopsy focus score between 1 and 2 and ranged
in age from 38 to 56 years.
The slides were deparafﬁnized and washed by diethyl
pyrocarbonate-dH20 (DEPC water), permeabilized in 0.1 N HCl for
15min at room temperature, and then washed in PBS followed by acet-
ylation for 15 min and washing in saline-sodium citrate buffer (SSC).
The slides were covered with probe solution (ebv-miR-BART13-3p, U6
as positive control, or scrambled siRNA as negative control) and dena-
tured at 75 °C for 12 min followed by incubation at 55 °C for 22 h.
A series of post-hybridization washes in 2X SSC, 1X SSC, 0.5X SSC,
and 0.25X SSC for 10 min each at 55 °C were conducted. Slides were
placed in blocking solution for 1 h at room temperature followed by in-
cubation in digoxigenin-AP Fab fragments (1:100) for 2 h, which was
followed by wash in PBS Tween for 15 min at room temperature and
then wash in alkaline phosphatase buffer for 10 min at room tempera-
ture. Slides were developed with 5-bromo-4-chloro-39-
indolyphosphate/nitro blue tetrazolium chloride and counterstained
with Nuclear Fast Red (Sigma Aldrich). Images were taken using a digi-
tal camera DP25 (Olympus) attached to light microscope BX41
(Olympus).
2.7.1. Double Fluorescent In Situ Hybridization/immunoﬂuorescence
To investigate the cell-speciﬁc distribution of ebv-miR-BART13-3p
in relation to the levels of STIM1 in FFPE human minor SG biopsies, a
double ﬂuorescent in situ hybridization/immunoﬂuorescence for ebv-mir-bart13/STIM1was performed. The slideswere deparafﬁnized in xy-
lene and ethanol solutions and placed in PBS. To uncover antigenic sites
of proteins to antibodies and expose cellular RNA to probes, the sections
were boiled in 10 mM citrate buffer pH 6 (Sigma Aldrich) for 10 min.
After 30 min of cooling, the slides were washed in water 3 times for
5 min. A prehybridization step was performed by incubating the slides
in 4× SSC (Crystalgen, Comaack, NY), 3% BSA (Sigma) buffer during
20 min at 55 °C. The 5′- and 3′- digoxigenin-labeled, locked nucleic
acid-modiﬁed DNA oligonucleotides complementary to the mature
ebv-miR-BART13-3p (Exiqon, Vedbaek, Denmark), scramble (negative
control) and U6 (positive control) (Exiqon) were denatured at 90 °C
for 4 min and diluted to a concentration of 25 nM, 25 nM and 5 nM, re-
spectively, in ISH buffer 1× (Exiqon) in a non-stick RNase-free tube.
After the pre-hybridization the diluted probeswere applied to the slides
(approx. 50 uL per piece of tissue) and covered using Frame-Seal Incu-
bation Chambers (Biorad, Hercules, CA). The hybridization was per-
formed for 1 h at 55 °C. The incubation chamber was detached. Then,
the slides were placed at room temperature in 5× SSC (Crystalgen)
and washed for 5 min at 55 °C in 5× SSC (1 wash), 1× SSC (2 washes),
0.5× SSC (2washes) and 5min at room temperature in buffer 0.2× SSC.
After washing for 5 min at room temperature in 1× PBS, the sections
were blocked with blocking reagent (3% BSA in TBS buffer, pH 7.4)
and incubated for 30minwith amouse anti-DIG unconjugated antibody
(Abcam Cat# ab420, RRID:AB_304362; dilution 1:500). The miRNA sig-
nal was detected with the Tyramide Signal Ampliﬁcation (TSA) kit
(Invitrogen) with Alexa Fluor 488 tyramide, following the
manufacturer's directions. After mRNA detection, the slides were
washed again in PBS and STIM1 was detected using rabbit anti STIM1
antibody (Cell Signaling Technology Cat# 5668S, RRID:AB_10828699).
The primary antibody was incubated overnight at 4 °C diluted 1:100
in blocking reagent. After 3washes in PBS buffer a Texas Red conjugated
antibody mouse anti-rabbit (Santa Cruz Biotechnology Cat# sc-53806,
RRID:AB_783986) diluted 1:300 in blocking reagent was incubated for
1 h at room temperature and wash in PBS. The slices were mounted in
with Prolong Gold anti-fade containing DAPI (Invitrogen). As negative
control rabbit no-immune antibodywas used instead of the primary an-
tibody. The slides were evaluated using a ﬂuorescentmicroscope VS120
virtual slide scanner (Olympus). Images were taken using the same ex-
posure time for all the samples analyzed. The scramble negative control
for the FISH did not show any signal under the conditions described. The
biopsies shown in Fig. 6 were from female, Caucasian SS subjects, with
focus score of 1, positive for anti-SSA autoantibodies, 55 and 67 years
old.
2.8. Real-time Quantitative PCR (qPCR)
qPCR was performed on total RNA extracted from transfected and
non-transfected cells. Reverse transcription (RT) was performed using
the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Sci-
entiﬁc, Waltham, MA, USA) according to the manufacturer's instruc-
tions, using 500 ng of total RNA. Taqman probes for the STIM1 and
GAPDH were used (Thermo Fisher Scientiﬁc, Waltham, MA, USA; part
no.HS00963373_m1 and part no.HS99999905_m1, respectively) ac-
cording to the protocol provided by the manufacturer. Brieﬂy, a 20-μl
RT reaction was run on a Veriti 96-Well Thermal Cycler (Applied
Biosystems, Foster City, CA) for 10 min at 25 °C, 120 min at 37 °C, and
5 min at 85 °C. qPCR was performed using on the StepOnePlus Real-
Time PCR Sytem (Applied Biosystems, Foster City, CA) with each reac-
tion run in triplicate. The 20-μl qPCR reaction was runwith cycling con-
ditions of 10min at 95 °C, followed by 40 cycles of denaturing for 15 s at
95 °C, and annealing and extending for 60 s at 60 °C.
2.9. Western Blots
Ebv-miR-BART13-3p transfected and mock-transfected HSG cells
were washed with phosphate-buffered saline (PBS) and lysed in RIPA
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hibitor Cocktail tablets (Roche Diagnostics, IN, USA). Lysates were
then centrifuged at 12,000 ×g for 30 min at 4 °C. Twenty micrograms
of protein was loaded and resolved in a 4%–12% NuPAGE gels
(Invitrogen, CA, USA). Anti-STIM1 (Cell Signaling Technology Cat#
5668S, RRID:AB_10828699), anti-Orai1 (Sigma-Aldrich Cat# AV50118,
RRID:AB_1848716), anti-STIM2 (Cell Signaling Technology Cat#
4917S, RRID:AB_2198021) anti-β-actin (Cell Signaling Technology
Cat# 3700P, RRID:AB_10828322), and Anti-TRPC1 antibody
(Willoughby et al., 2014) were used at 1:1000, 1:1000, 1:1000, and
1:400 dilution, respectively. Protein bands were detected by chemilu-
minescence and exposed to X-ray ﬁlm (Kodak, New York).
2.10. Cytosolic Ca+2 Measurements
HSG cells were transfected with ebv-miR-BART13-3p for 48 h in
glass bottom MatTek tissue culture dishes (MatTek Corp. Ashland,
MA). Measurements were performed by imaging Fura-2 loaded cells
using the Olympus IX50microscope and Polychrome 4 (TILL Photonics)
system. Images were acquired using a Photometrics CoolSNAP HQ cam-
era (Photometrics) and the MetaFluor software (MetaFluor Fluores-
cence Ratio Imaging Software, RRID:SCR_014294). Each ﬂuorescence
trace (340/380 nm ratio) represents an average from between 50 and
150 cells from at least 6 individual experiments. Student's t-test was
used to statistically evaluate the data.
2.11. NFAT Nuclear Translocation
Translocation of NFAT in control and ebv-miR-BART13-3p
transfected HSG cells was observed using an Olympus IX81 motorized
inverted microscope (Olympus) a TIRF-optimized Olympus Plan APO
60× (1.45 NA) oil immersion objective. Images were collected using a
Rolera EM-C2 camera (Q Capture software, RRID:SCR_014432) and
theMetaMorph imaging software (MetaMorphMicroscopyAutomation
and Image Analysis Software, RRID:SCR_002368). MetaMorph was also
used to measure the ﬂuorescence intensity in the nucleus and cyto-
plasm before and after stimulation with thapsigargin. Regions of inter-
est (ROI) were selected to obtain the values for their ﬂuorescence
intensities during a time course experiment. These values were then
plotted using the Origin 8 software (Origin, RRID:SCR_014212).
2.12. miRNA Target Predictions
The RNA22 batch script, available at https://cm.jefferson.edu/rna22/
Interactive/, was used to submit custom queries to the RNA22 server
with default settings. A manually curated list of genes involved in sali-
vary function was used to retrieve 116 corresponding transcript se-
quences and annotations from the NCBI Genomes database for the
GRCh38 assembly and the mature miRNA sequence for ebv-miR-
BART13-3p was taken from miRBase, version 21.
3. Results
3.1. Ebv-miR-BART13-3p Targets STIM1 and AQP5 Expression in Salivary
Gland Cells
In our previous study (Alevizos et al., 2011), we reported that ebv-
miR-BART13-3p was differentially expressed in patient SGs, showing a
greater than 22-fold increase, and the upregulation of this miRNA was
validated using independent samples with quantitative real time PCR
(qPCR). The RNA22 and RNAhybrid algorithms (Miranda et al., 2006;
Rehmsmeier et al., 2004) were used to identify potential targets for
ebv-miR-BART13-3p on mRNAs of genes involved in SG function.
Among these, STIM1 and AQP5, two critical components of salivary
ﬂuid secretion, contained predicted target sites with promising binding
energies and scoring metrics produced by each algorithm. Thesealgorithms predicted the binding of ebv-miR-BART13-3p to three po-
tential sites on STIM1 mRNAs, two located in the 3′UTR (folding ener-
gies of −30 and −27 Kcal/mol) and one in the coding sequence
(folding energy of−30.5 Kcal/mol). In the case of the AQP5 transcript,
the binding was predicted to be in the 3’UTR with a folding energy of
−30.5 Kcal/mol.
To conﬁrm the predicted binding sites on STIM1 mRNA, we con-
structed plasmids containing either the 3′ UTR (STIM1-3′UTR) or the
coding sequence of STIM1 (STIM1-CDS) downstream of a ﬁreﬂy lucifer-
ase gene driven by a CMV promoter. HSG cells, a human submandibular
gland ductal cell line, were transfected with either plasmid together
with an ebv-miR-BART13-3p analog for 48 h and then used to deter-
mine luciferase activity reﬂecting STIM1 transcription. Ebv-miR-
BART13-3p signiﬁcantly decreased luciferase expression by 40% when
co-transfected with the STIM1–3′UTR and 35% when co-transfected
with the STIM1-CDS (Fig. 1 A). Luciferase activity was not altered in
cells expressing the luciferase vector in the absence of the ebv-miR-
BART13. Together, these data show that ebv-miR-BART13-3p binds to
both the coding sequence and the 3′UTR of STIM1 mRNA.
We also validated the binding of ebv-miR-BART13-3p to the other
predicted target, AQP5. Since HSG cells express AQP5 at very low levels,
we used human-derived primary epithelial cells (pSG) that maintain an
acinar-like differentiation and strongly express AQP5 under certain con-
ditions (Jang et al., 2014). Luciferase assays were performed after co-
transfecting pSG cells with ebv-miR-BART13-3p and a Luciferase plas-
mid containing AQP5 3′UTR. After 48 h of co-transfection, ebv-miR-
BART13-3p induced a 30% decrease in luciferase activity. In contrast,
co-transfection with both the ebv-miR-BART13-3p analog and inhibitor
did not signiﬁcantly alter the luciferase activity when compared to con-
trol, non-transfected cells (Fig. 1B). Additionally, we observed a signiﬁ-
cant decrease in both AQP5 mRNA (Fig. 1C) and protein (Fig. 1D) in the
ebv-miR-BART13-3p transfected pSG cells.
3.2. Ebv-miR-BART13-3p Downregulates STIM1 Expression and Impairs
SOCE in Human Salivary Gland Epithelial Cells
To further characterize the effect of ebv-miR-BART13-3p on SG cell
function, the miRNA was overexpressed in HSG and pSG cells. STIM1
protein level decreased in both sets of cells under these conditions, as
shown by Western Blot (Fig. 2A). However, the mRNA levels of STIM1
did not change signiﬁcantly in the ebv-miR-BART13-3p transfected
HSG cells when compared to the scrambledmiRNA transfected controls
(Fig. 2B). This suggests that ebv-miR-BART13-3p inhibits translation of
STIM1 but does not degrade its transcript. The decreased level of
STIM1 in ebv-miR-BART13-3p-transfected HSG cells was further con-
ﬁrmed by immunoﬂuorescence staining of STIM1 (Fig. 2C), which
shows a 40% decrease in overall area-normalized intensity. Notably, ex-
pression of other critical proteins involved in SOCE in SG acinar cells,
such as STIM2, ORAI1 and TRPC1, were unaffected by ebv-miR-
BART13-3p treatment (Fig. 2A).
Since STIM1 is a primary regulator of SOCE, we tested the effects of
ebv-miR-BART13-3p on SOCE in HSG and pSG cells. By using
thapsigargin (Tg), a SERCA pump inhibitor, we observed that whileTg-
stimulated intracellular Ca2+ release (Ca2+ increase induced by Tg in
Ca2+-freemedium)was not altered in ebv-miR-BART13-3p-transfected
cells, there was a drastic decrease in the Ca2+ entry (i.e. peak Ca2+ in-
crease after re-addition of calcium to cell medium) (Fig. 2D).
3.3. Ebv-miR-BART13-3p Disrupts SOCE-dependent NFAT Activation
Ca2+-entry via SOCE is required for activation of the transcription
factorNFAT. Theﬁrst step in this process involves Ca2+-CaM-dependent
activation of calcineurin and dephosphorylation of NFAT. Once dephos-
phorylated, NFAT translocates from the cytosol into the nucleus. To as-
sess if the ebv-miR-BART13-3p-induced decrease in STIM1 and SOCE
alters NFAT activation, a GFP-NFAT plasmid was transfected with or
Fig. 1. ebv-miR-BART13-3p targets both STIM1 and AQP5. (A) Luciferase reporter vector alone (CTRL plasmid) or a vector containing either STIM1-3′UTR or STIM1-CDS were co-
transfected with or without ebv-miR-BART13-3p in HSG cells. Luciferase activities were measured after 48 h. Data are expressed as percent change of mean ± S.E. RLU over the
control condition from three independent experiments with quadruplicated samples. (B) Luciferase reporter containing the AQP5-3′UTR construct was co-transfected with indicated
miRNA or miRNA inhibitor into pSG cells. Luciferase activities were measured after 48 h. Data are expressed as percent change of mean ± S.E. RLU over the control condition from
three independent experiments with quadruplicated samples. (C) Change in AQP5 expression in pSG cells transfected with or without ebv-miR-BART13-3p. Data are presented as a
mean of the RQ values and error bars represent 95% conﬁdence intervals from three independent experiments. (D) Western blotting of AQP5, STIM1 and β-actin in pSG cells
transfected with or without ebv-miR-BART13-3p.
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Tg and NFAT localizationwasmonitored by live ﬂuorescence imaging of
single cells. Control cells showed a complete translocation of GFP-NFAT
from the cytoplasm to the nucleuswithin 30min after the addition of Tg
(Fig. 3 A), indicated by an increase in GFP signal in the nucleus and cor-
responding decrease in the cytosolic signal. In contrast, GFP-NFAT
remained in the cytosol and did not translocate into the nucleus in
cells transfected with ebv-miR-BART13. Moreover, co-transfection of
ebv-miR-BART13-3p with its inhibitor mitigated its effects on GFP-
NFAT (Fig. 3C). This suggests that NFAT activation is decreased in cells
treated with ebv-miR-BART13-3p, which was further conﬁrmed by ex-
amining more long-term consequences of NFAT activation by using
NFAT-reporter plasmid to demonstrate NFAT-dependent gene expres-
sion. Consistent with the decrease in NFAT translocation into the nucle-
us, ebv-miR-BART13-3p-transfected cells displayed a 50% decrease in
the NFAT-dependent luciferase activity compared to control cells (Fig.
3B). Together the data demonstrate that the ebv-miR-BART13-3p in-
duced downregulation of STIM1 leads to the disruption of SOCE and rel-
evant Ca2+-dependent gene expression.
3.4. Ebv-miR-BART13-3p is Present in Salivary Glands of pSS Patients
To localize the cellular expression of the ebv-miR-BART13-3p in the
pSS SGs, we performed in situ hybridization (ISH) with LNA-stabilized
mIRNA probes. There was a strong presence in both acinar and ductal
cells, especially those surrounded by inﬂammatory cells. In SG from
healthy volunteers, this viral miRNA had very minimal presence or
was absent (Fig. 4A). This was consistent with the detection of highlevels of the microRNA in SGs from pSS patients compared to healthy
volunteers that we observed with microarrays (Alevizos et al., 2011).
To further investigate the inverse relationship of the ebv-miR-
BART13-3p to the protein levels of STIM1 in pSS SGs, we performed a
double ﬂuorescent ISH/immunoﬂuorescence in FFPE human minor SG
biopsies for ebv-miR-BART13-3p and STIM1. This method allowed us
to discern simultaneously the presence of the microRNA and its target
in the same cell. We observed that STIM1 protein level was relatively
low in epithelial cells where ebv-miR-BART13-3p was detected at rela-
tively high levels, whereas neighboring epithelial cells that lacked the
miRNA displayed higher levels of STIM1 (Fig. 5). These results support
the in vitro experiments and provide further evidence that the presence
of ebv-miR-BART13-3p is associatedwith a decrease in STIM1within SG
epithelial cells.
Ebv-miR-BART13-3p is encoded by EBV and is usually detected in
cells infected by the virus.While themain targets of EBV during chronic
latent infections are B lymphocytes, it is presently unclear if SG epithe-
lial cells can be readily infected by EBV (Hutt-Fletcher, 2007). Since the
binding of EBV to its receptor CD21 is required for EBV to infect cells, we
examined the localization of CD21 in SG samples (Nemerow et al.,
1985). As shown in Fig. 6, CD21 is expressed in CD20+ inﬂammatory
cells, but not in salivary ductal or acinar cells. Therefore, although sali-
vary epithelial cells from pSS patients lack the receptor required for
EBV infection, they can still be infected by ebv-miR-BART13-3p. This
suggests that a mechanism other than direct EBV infection of epithelial
cells accounts for the presence of ebv-miR-BART13-3p into epithelial
cells. One possible mode of such transfer is via exosomes (Pegtel et al.,
2010).
Fig. 2. STIM1 expression and SOCE in HSG cells is altered by ebv-miR-BART13-3p. HSG cells were transfected with or without ebv-miR-BART13-3p and STIM1, STIM2, ORAI1, TRPC1, β-
actin protein expression was determined by Western blotting (A) and STIM1 transcript level was measured by qPCR, expressed at the cycle threshold (Ct) value (B). (C)
Immunoﬂuorescence staining of STIM1 (green) in HSG cells transfected without (left panel) or with ebv-miR-BART13-3p (right panel). Cell nuclear was stained with DAPI (blue). The
bar represents 20 μm. (D) HSG cells transfected without (black) or with ebv-miR-BART13-3p (red) were loaded with Fura-2-AM and treated with Tg (1 uM) and subsequent add back
CaCl2 (1 mM). Each ﬂuorescence trace (340/380 nm ratio) represents an average from 50 to 150 cells from six individual experiments. Right panel in (D) shows averaged data for
internal Ca2+ release and Ca2+ inﬂux.
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Salivary Epithelial Cells
To determine whether transfer through exosomes is a potential
mechanism whereby this viral miRNA could be introduced to epithelial
cells from the resident B cell in minor SGs, we used a co-culture exper-
iment. In a Transwell® system, salivary epithelial cells were cultured in
the lower chamber with a B cell line stably infected with EBV (X50-7),
which constitutively expresses ebv-miR-BART13-3p, separated by a
membrane with a pore size of 0.4 μm. This pore size is permissible to
exosomes but notmost likey not whole EBV viral particles. Additionally,
X50-7 cells are in the EBV type III latency phase (Cameron et al., 2008)
and in this phase, latency does not result in production of virions
(Odumade et al., 2011).
After 8 days of co-culture, there was a 3-fold increase in ebv-miR-
BART13-3p levels in the SG cells compared to control cells (Fig. 7A).
By isolating exosomal RNA(Gallo and Alevizos, 2013), we further con-
ﬁrmed the presence of ebv-miR-BART13-3p within exosomes isolated
from salivary/B-cell co-cultured media but not from media where B
cells were not seeded (no qPCR ampliﬁcation of the miRNA in this
media after 40 cycles of ampliﬁcation) (Fig. 7B). This important experi-
ment demonstrates that ebv-miR-BART13-3p can be effectively trans-
ferred from B cells to epithelial cells via exosomes. The functional
effect of exosomally transferred ebv-miR-BART13-3p in SG cellswas de-
termined by assessing STIM1 protein levels and SOCE. In the co-cultured
epithelial cells, we observed a 40% decrease in STIM1 protein compared
to the control condition. Additionally, Tg-stimulated Ca2+ measure-
ments revealed a signiﬁcant delay in Ca2+ inﬂux in the co-culturedcells, similar to cells transfected directly with ebv-miR-BART13-3p
(Fig.7 C).
4. Discussion
While the underlying pathogenesis of pSS is poorly understood, the
most widely accepted model holds that the chronic lymphocytic inﬁl-
tration of the glands leads to progressive tissue damage and secretory
defects (Voulgarelis and Tzioufas, 2010). However, the degree of both
the lymphocytic inﬁltration and SG dysfunction varies from patient to
patient and there is not a strong correlation between the two
(Alevizos et al., 2011). Viruses have been hypothesized to play a role
in the initiation or maintenance of inﬂammation but a link with SG ep-
ithelial cell dysfunction has not yet established. In this study, we have
demonstrated that ebv-miR-BART13-3p, a miRNA encoded by the Ep-
stein-Barr virus (EBV), is expressed at high levels in the SGs of pSS pa-
tients but not in healthy individuals. Furthermore, this study
demonstrates that this miRNA can be transferred from EBV-infected B
lymphocytes to SG epithelial cells via exosomes, where it decreases
STIM1 and AQP5 protein levels. The decrease in STIM1 adversely affects
the regulation of calcium signaling and NFAT activation. Together our
data suggest a mechanism by which EBV can contribute to the exocrine
dysfunction in SS.
After primary infection with EBV, the virus can persist in a latent
formwithinmemory B-cells. There are contradictory reports in the liter-
ature about the presence of EBV in the SG of SS patients. Several studies
have shown that up to two thirds of SS patients have detectable EBV in
the SGs compared to a low (0–15%) percentage of controls (Fox et al.,
Fig. 3. Effects of ebv-miR-BART13-3p on SOCE-dependent NFAT translocation and activation (A) Nuclear translocation of GFP-NFAT in HSG cells co-transfected pGL4.30 (luc2P/NFAT-RE/
Hygro) without ebv-miR-BART13-3p, with ebv-miR-BART13-3p, or co-transfected with an inhibitor of ebv-miR-BART13-3p. Cells were treated with Tg, and the ﬂuorescence signal was
measured in the cytosol (red) and nucleus (black) for 30 min. Values are shown relative to the initial ﬂuorescence in these two different cellular compartments. (B) HSG cells were co-
transfected with pGL4.30(luc2P/NFAT-RE/Hygro) plasmid together with (white) or without (black) ebv-miR-BART13-3p. Luciferase activity was measured as described above. Data are
shown as RLU of mean ± S.E. from three separate experiments.
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similarly high frequencies in SS but no difference when compared to
healthy controls (Deacon et al., 1992; Maitland et al., 1995; Venables
et al., 1989), whereas a third group of studies reported a much lower
frequency in SS (Merne and Syrjanen, 1996; Perrot et al., 2003;
Schuurman et al., 1989). Similarly, there are conﬂicting studies about
the cellular localization of EBV in the SGwith some ﬁnding it in both ep-
ithelial and lymphoid cells (Horiuchi et al., 1999; Wen et al., 1996),
whereas others report its localization mainly in the epithelial cells
(Mariette et al., 1991; Karameris et al., 1992). These differences may
be explained, to a large extent, by technical differences in the method
of detection. In the present study, we chose an alternative approach
and assessed the presence of CD21, the receptor for EBV, to identify
which cells were likely to be infected by the virus (Nemerow et al.,
1985). We show that CD21 receptors are present on inﬂammatory
cells but not on salivary epithelial cells. These data suggest that the pres-
ence of ebv-miR-BART13-3p in epithelial cells is unlikely to be result of
direct EBV infection of these cells. One study showed that EBV miRNAs
can be transferred from EBV-infected B lymphocytes to non-B-lympho-
cytes via exosomes (Pegtel et al., 2010). Here we show that ebv-miR-
BART13-3p can be effectively transferred via exosomes from Blymphocytes to epithelial cells that are lacking the CD21 receptor.
These in vitro results provide a plausible mechanism to explain the in
vivo presence of EBV miRNAs in salivary epithelial cells lacking the
EBV receptor and may provide an important missing link to better ex-
plore the possible role of EBV in pSS and other autoimmune diseases.
Importantly, we show that the exosomal ebv-miR-BART13-3p retains
its function and effectively inhibits translation of its targets, STIM1 and
AQP5, which are two key molecules of the physiologic function of sali-
vary epithelial cells.
In a previously published study (Alevizos et al., 2011), we have
shown that several of the EBV miRNAs were highly expressed in SGs
of pSS patients when compared to controls. Here, we show that ebv-
miR-BART13-3p binding sites are located in both the CDS and 3’UTR of
STIM1 and binding of ebv-miR-BART13-3p to either element decreased
the translation of STIM1, even though the level of mRNA did not change
signiﬁcantly. Further, we show a decrease in STIM1 protein levels in
cells treated with ebv-miR-BART13-3p. This is consistent with the sug-
gestion that some microRNAs regulate mRNA translation by either
degrading their target transcripts or by blocking their translation
(Kong et al., 2008). Importantly, our ﬁndings show that a decrease in
STIM1 levels lead to impaired calcium signaling and nuclear
Fig. 4. Presence of ebv-miR-BART13-3p in minor SG tissue sections. In situ hybridization (ISH) on tissue sections from healthy controls (A, B) and SS patients (C, D) with probes for ebv-
miR-BART13-3p (A–D) or a scrambledmiRNA negative control (F) or Poly dT positive control (G). The lymphocytic inﬁltrate with ebv-miR-BART13-3p stainingwas shown (E and E′). The
A′–E′ represent each insert (white box) from each corresponding graph (A–E), respectively. Slides were developed with 5-bromo-4-chloro-39-indolyphosphate/nitro blue tetrazolium
chloride and counterstained with Nuclear Fast Red.
223A. Gallo et al. / EBioMedicine 10 (2016) 216–226translocation of NFAT. As noted above, STIM1 is an ER-Ca2+ sensor pro-
tein,which has been established as the regulator of SOCE channels (Liou
et al., 2005). SOCE has an indispensable role in regulating various cellu-
lar functions, including salivary secretion. Saliva secretion is a tightly
regulated and coordinated process of severalwater and ion transporters
and channels that requires Ca2+ as a driving factor in the salivary acinar
cells (Ishikawa et al., 2006; Catalan et al., 2009). First, neurotransmitters
activatemembrane receptors, such asMuscarininc-3 Receptor, generat-
ing the intracellular second messenger, inositol 1,4,5, trisphosphate,
that induces internal Ca2+ release, and Ca2+ inﬂux. This increase in
the cytosolic [Ca2+] regulates the activity of ion transporters such as
NKCC1, Ca2+-activated K+ channels, and the Ca2+-activated Cl− chan-
nels. Together, these ion ﬂuxes generate an osmotic gradient that drives
the movement of water into the lumen of acinus. Therefore, alterations
in this signaling cascade, including disruption of SOCE, will directly af-
fect many steps in the regulatory pathways of salivary secretion. Our
ﬁndings reported here, demonstrate an importantmechanism that sug-
gests that disruption in Ca2+ inﬂux could contribute to the SG dysfunc-
tion and xerostomia seen in SS patients. Interestingly, by searching for
more predicted targets of genes involved in salivary gland fucntion,
we found that ebv-miR-BART13-3p, might potentially also target
SERCA pumps (Supplemental Table 1). Furtherworkwill aim to identifythe global changes induced by this microRNA in salivary epithelial cells
especially as they relate to its coordinated effect not only on speciﬁc
genes but rather on speciﬁc pathways.
In summary, we have showed that a functional EBV microRNA, ebv-
miR-BART13, can be transferred from B cells to salivary epithelial cells
where it down-regulates STIM1 protein and thus impacts activation of
a critical Ca2+ entry mechanism required for ﬂuid secretion. Attenua-
tion of Ca2+ entry also decreases activation of NFAT and NFAT-depen-
dent transcriptional activity. Moreover, we have shown that ebv-miR-
BART13-3p also down-regulates the expression of AQP5, an important
water channel located on the apical membrane of polarized human SG
acinar cells. Altogether, our results demonstrate a functional link be-
tween ebv-miR-BART13-3p and loss of saliva secretion, in SS SGs and
suggest that ebv-miR-BART13-3p could be a therapeutic target for im-
proving xerostomia in SS patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.06.041.
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Fig. 5. ebv-mir-bart13-3p co-localizes with STIM1 in humanminor salivary glands. Immunoﬂuorescence staining of STIM1 (red) and ISH of ebv-miR-BART13-3p (green) were performed
on parafﬁn embedded sections fromminor SGs biopsies of the healthy control (A–C) and of SS patientwith focus score 2 to 3 and low salivaryﬂow (D-F). Scale bars represent 50 μm.D′–F′
are higher magniﬁcation of the areas (white box) indicated in D–F, respectively, with scale bars representing 20 μm. G–I is the control staining of U6 (positive control of ISH). Acini are
indicatedwith “a”; ducts are labeledwith “d” and the arrows indicated inﬂammatory cellswith high signal for ebv-miR-BART13-3p -3p in close proximity to aciniwith low levels of STIM1.
Fig. 6. EBV-receptor (CD21) expression is restricted to inﬁltrating B-cells in minor SGs of SS patients. Immunoﬂuorescence staining of CD20 (green) and CD21 (red) was performed on
parafﬁn embedded sections from minor SGs biopsies. A to H correspond to representative images from two SS patients. D′ and H′ correspond to a higher magniﬁcation of the areas
(white box) of D and H, respectively. The inﬂammatory cells surrounding the ducts (d) correspond in high proportion to B cells. Both immature B cells (CD20+ cells and CD20+/
CD21+) and mature B cells (just CD21+) are found in close proximity to ducts shown in D. Scale bars represent 20 μm.
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Fig. 7. Exosomal transfer of functional ebv-miR-BART13-3p -3p fromB cells to salivary epithelial cells. (A)Measurement of transferred ebv-miR-BART13-3p (Real-time PCR) in pSG culture
co-culture with no cells in upper chamber of transwell insert (control) or with lymphocytic cell line X50-7. The plots show mean ± S.E. from triplicated samples from three different
experiments. (B) The presence on ebv-miR-BART13-3p in exosomes was evaluated by real-time PCR in the X50-7 cells and in the exosomal fraction isolated from the conditioned
medium, presented as a mean of the RQ values with error bars representing 95% conﬁdence intervals from triplicated samples from three different experiments. (C) Representative
Western blotting for STIM1 and the β-actin protein in pSG cells co-cultured without (control) or with X50-7 cells. (D) Calcium release and entry in Fura-2 loaded pSG Control (black)
and pSG co-cultured with X50-7 cells (red). Each ﬂuorescence trace (340/380 nm ratio) represents an average from 50 to 150 cells from 3 independent experiments.
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